A pilot study of Octreotide LAR® vs. octreotide tid for pain and quality of life in chronic pancreatitis

Journal of the Pancreas

Volumn 10, Issue 5, 2009, Pages 518-522

  Lieb II, John G ^a   Shuster, Jonathan J ^b   Theriaque, Douglas ^b   Curington, Cheryl ^a   Cintron, Miriam ^a   Toskes, Philip P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Chronic; Injections; Intramuscular; Octreotide; Pain; Pancreatitis; Quality of life

Indexed keywords

LONG ACTING DRUG; MORPHINE; OCTREOTIDE; OCTREOTIDE LAR; PANCRELIPASE; SHORT ACTING DRUG; ULTRASE MT 20; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; GALLBLADDER DISEASE; GALLBLADDER SLUDGE; HUMAN; PAIN ASSESSMENT; PATIENT SATISFACTION; PILOT STUDY; QUALITY OF LIFE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ABDOMINAL PAIN; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATITIS, CHRONIC; PILOT PROJECTS; QUALITY OF LIFE;

EID: 70349275753     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 2005; 13 (158):1-99.
2. Thomopoulos KC, Pagoni NA, Vagenas KA, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduced the incidence of post-ERCP pancreatitis. Gastrointestinal Endoscopy. 2006: 64(5) 726-31.
3. Foster E, Leung J. Pharmacotherapy for the prevention of post ERCP pancreatitis. Am J Gastroenter. 2007: 102: 52-5.
4. Testoni PA. Facts and Fiction in the pharmacologic treatment of post ERCP pancreatitis: a never ending story. Gastrointestinal Endosc. 2006: 64, No 5. 732-3.
5. Toskes PP, Forsmark CE, DeMeo MT, Prinz RA, Owyang C, Soudah H, DiMagno EP, Nealon WH, Vinayek R, Banks PA, Adams D, Warshaw A, and Katkov W. A multicenter controlled trial of octreotide for the pain of chronic pancreatitis. Pancreas [abstract] 8:774, 1993.
6. Toskes PP; Forsmark CE; Demeo MT; Prinz RA; Owyang C; Soudah H; Dimagno EP; Nealon WH; Vinayek R Banks PA, Adams D, Warshaw A and Karkov W. An open-label trial of octreotide for the pain of chronic pancreatitis. Gastroenterology. [abstract] 106(4 SUPPL.). 1994. A326.
7. Loginov AS, Sadokov VM, Vinokurova LV, Chernoiarova OD, Astaf'eva OV, Nilova TV. A trial of the use of sandostatin in patients with chronic pancreatitis. Ter Arkh. 1995; 67 (7):60-2. Russian.
8. Schmalz MJ, Soergel KH, Johnason JF. The effect of octreotide acetate (sandostatin) on the pain of chronic pancreatitis. Gastroenterology 1992; [abstract] 102 suppl 2: A290.
9. Malfertheiner P, Mayer D, Büchler M, Domínguez-Muñoz JE, Schiefer B, Ditschuneit H. Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. Gut. 1995; 36 (3):450-4.
10. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L J. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Clin Oncol. 1999 Feb;17(2):600-6.
11. Woltering EA, Salvo VA, O'Dorisio TM, Lyons J 3rd, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P, Mamikunian G. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas. 2008 Jul;37(1):94-100.
12. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol. 2001;12 Suppl 2:S105-9.
13. Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clin Endocrinol (Oxf). 1999 Feb;50(2):245-5.
14. Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs. 1997 Apr;53(4):681-99.
15. Eisen GM, Sandler RS, Coleman SD, Foxx-Orenstein A, Tarnasky P, Cotton PB. Development of a disease specific measure for Health Related Quality of Life for patients with chronic pancreatitis. Gastroenterology. Supplements [abstract]. Vol 108. No. 4. 1995. Page A12.
16. Narcotic Analgesics Comparative Review. DRGDEX Consults - Micromedex Healthcare Series, 2007. Thomson Reuters: New York, NY, USA.
17. Shuster JJ. Student t-tests for potentially abnormal data. Statistics in Medicine. 2009 Jul 20;28(16):2170-84.